RNAC FY 2018 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RNACCartesian Therapeutics, Inc.

$216M

FY 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$903,000+336.2% YoY

Gross Profit

$903,000100.0% margin

Operating Income

-$65M-7200.7% margin

Net Income

-$65M-7235.4% margin

EPS (Diluted)

$-87.55

Cash Flow

Operating Cash Flow

-$59M

Free Cash Flow

-$60M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$44M

Total Liabilities

$50M

Stockholders' Equity

-$5M

Cash & Equivalents

$37M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$903,000	$207,000	+336.2%
Gross Profit	$903,000	$207,000	+336.2%
Operating Income	-$65M	-$64M	-1.9%
Net Income	-$65M	-$65M	-0.0%